CCFP
IBB icon

Charles Carroll Financial Partners’s iShares Biotechnology ETF IBB Stock Holding History

Charles Carroll Financial Partners’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,485
Closed -$1.29M – 43
2021
Q4 		$1.29M Buy
+8,485
New +$1.31M 1.29% 23

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Carroll Financial Partners's IBB Position: Q1 2022 in Review

Charles Carroll Financial Partners sold out of iShares Biotechnology ETF (IBB) in Q1 2022, closing a stake of 8,485 shares — an estimated $1.29M sold.

Charles Carroll Financial Partners first reported a position in IBB in Q4 2021 and held it in 1 quarter. The position peaked at $1.29M in Q4 2021. 897 funds tracked by Wall St. Rank hold IBB as of Q1 2022.

  • Charles Carroll Financial Partners reported no remaining iShares Biotechnology ETF position as of Q1 2022 after selling out during the quarter.
  • Charles Carroll Financial Partners sold 8,485 iShares Biotechnology ETF shares in Q1 2022, an estimated $1.29M.
  • Charles Carroll Financial Partners first reported a position in iShares Biotechnology ETF in Q4 2021 and held it in 1 quarter.
  • Charles Carroll Financial Partners's iShares Biotechnology ETF position peaked at $1.29M in Q4 2021.
  • 897 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2022.

Based on Charles Carroll Financial Partners's 13F filing for Q1 2022, filed 12 May 2022.